One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid
Hormone-related Protein, PTHrP, that can be given safely over one week. The investigators
plan to infuse low doses of intravenous PTHrP to determine if it leads to a sustained and
progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy
(HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally,
the investigators will assess the direct influence of PTHrp on markers of bone turnover, and
plasma 1,25 (OH)2 vitamin D regulation in healthy human volunteers.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Hormones Parathyroid Hormone Parathyroid Hormone-Related Protein